سعر اوفلوسويكس 0.3% قطرة للعين 5مل 2024

Ofloswix 0.3% ophth.solution 5 ml: Ofloxacin 0.3% ophthalmic solution (5 ml bottle) marketed in Egypt by Chemipharm.

• Bacterial conjunctivitis caused by susceptible organismsPopulation: Adults and children aged 1 year and olderDailyMed (U.S. National Library of Medicine)
• Bacterial corneal ulcers caused by susceptible organismsPopulation: Adults and children aged 1 year and olderDailyMed (U.S. National Library of Medicine)

• Most frequent: transient ocular burning or discomfort. Others: stinging, redness, itching, chemical conjunctivitis/keratitis, periocular/facial oedema, foreign-body sensation, photophobia, blurred vision, tearing, dryness, eye pain; rarely dizziness and nausea.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to ofloxacin, to other quinolones, or to any component of the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with systemic quinolones; discontinue at the first sign of rash or allergic reaction.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Prolonged use may result in overgrowth of non-susceptible organisms, including fungi; discontinue and use alternative therapy if superinfection occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Theophylline, caffeine, warfarin, ciclosporin (systemic quinolone data)No specific interaction studies with the eye drops; systemic quinolones have raised theophylline levels, interfered with caffeine metabolism, enhanced warfarin effect and been associated with transient serum creatinine rises with ciclosporin.DailyMed (U.S. National Library of Medicine)

• Embryocidal effects only at very high oral doses in rats and rabbits; no adequate studies in pregnant women. Use in pregnancy only if the benefit justifies the potential risk to the fetus (US label, older format).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Oral ofloxacin passes into human milk at concentrations similar to plasma; excretion after ophthalmic use is unknown. Decide whether to discontinue nursing or the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ofloxacin: Inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication.